Octagon Capital Advisors logo

Octagon Capital Advisors

North America, New York, United States, New York

Description

Octagon Capital invests in public and private healthcare companies globally.

Investor Profile

Octagon Capital Advisors has made 58 investments, with 2 in the past 12 months and 7% as lead.

Stage Focus

  • Series C (31%)
  • Series B (26%)
  • Post Ipo Equity (16%)
  • Series A (12%)
  • Series E (5%)
  • Series Unknown (5%)
  • Series D (3%)
  • Private Equity (2%)

Country Focus

  • United States (55%)
  • China (38%)
  • Switzerland (3%)
  • United Kingdom (2%)
  • Singapore (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Pharmaceutical
  • Medical
  • Oncology
  • Biopharma
  • Medical Device
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Octagon Capital Advisors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 12
HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 6
Casdin Capital
North America, New York, United States, New York
Co-Investments: 8
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 12
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 6
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 6
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 6
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 13
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 7
Invus
North America, New York, United States, New York
Co-Investments: 6

Which angels does Octagon Capital Advisors often collaborate with?

MC
North America, California, United States, San Francisco
Shared Deals: 1
Adrian Cheng
Asia, Hong Kong
Shared Deals: 2

What are some of recent deals done by Octagon Capital Advisors?

Numab

Wadenswil, Zurich, Switzerland

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

BiopharmaBiotechnologyHealth CareHealth DiagnosticsLife ScienceMedicalTherapeutics
Series CJan 9, 2025
Amount Raised: $54,939,501
Bluejay Therapeutics

San Mateo, California, United States

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

BiotechnologyHealth CarePharmaceutical
Series CMay 9, 2024
Amount Raised: $182,000,000
Century Therapeutics

Philadelphia, Pennsylvania, United States

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

BiotechnologyHealth CareHealth Diagnostics
Post Ipo EquityApr 11, 2024
Amount Raised: $60,000,000
Unicycive Therapeutics

Los Altos, California, United States

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

BiotechnologyHealth CareHealth DiagnosticsMedical
Post Ipo EquityMar 14, 2024
Amount Raised: $50,000,000
Regulus Therapeutics

San Diego, California, United States

Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.

BiotechnologyGeneticsHealth CareTherapeutics
Post Ipo EquityMar 12, 2024
Amount Raised: $100,000,000
MindMed

New York, New York, United States

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityMar 7, 2024
Amount Raised: $175,000,000
ProfoundBio

Seattle, Washington, United States

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

BiotechnologyOncologyTherapeutics
Series BFeb 13, 2024
Amount Raised: $112,000,000
Tenaya Therapeutics

San Francisco, California, United States

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease.

BiopharmaBiotechnologyHealth CareTherapeutics
Post Ipo EquityFeb 8, 2024
Amount Raised: $50,000,000
Pepgen

Oxford, Oxfordshire, United Kingdom

PepGen is empowering nucleic acid therapeutics to go the distance.

BiotechnologyClinical TrialsMedical
Post Ipo EquityFeb 7, 2024
Amount Raised: $80,100,000
Dianthus Therapeutics

Waltham, Massachusetts, United States

Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityJan 22, 2024
Amount Raised: $230,000,000